ImmunityBio explodes 320% on Anktiva launch in Saudi Arabia

ImmunityBio (IBRX) rose 4% premarket as its immunotherapy Anktiva launched in Saudi Arabia for bladder and lung cancer. The stock has surged 320% this year. This follows partnerships to enter the MENA region and SFDA approval. Anktiva is now approved in 5 jurisdictions covering 34 countries, boosting its global presence.